| Stereochemistry | ABSOLUTE |
| Molecular Formula | C45H56F2N6O8S2 |
| Molecular Weight | 911.088 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@]1(NC(=O)[C@]3([H])C[C@H](CN3C(=O)[C@@H](CC(=O)N4CCCC(F)(F)C4)CCCCCC=C2)OC5=CC(=NC6=C(C)C(OC)=CC=C56)C7=NC(=CS7)C(C)C)C(=O)NS(=O)(=O)C8CC8
InChI
InChIKey=UDMJANYPQWEDFT-ZAWFUYGJSA-N
InChI=1S/C45H56F2N6O8S2/c1-26(2)34-24-62-41(49-34)33-21-37(32-15-16-36(60-4)27(3)39(32)48-33)61-30-20-35-40(55)50-45(43(57)51-63(58,59)31-13-14-31)22-29(45)12-9-7-5-6-8-11-28(42(56)53(35)23-30)19-38(54)52-18-10-17-44(46,47)25-52/h9,12,15-16,21,24,26,28-31,35H,5-8,10-11,13-14,17-20,22-23,25H2,1-4H3,(H,50,55)(H,51,57)/b12-9-/t28-,29-,30-,35+,45-/m1/s1
| Molecular Formula | C45H56F2N6O8S2 |
| Molecular Weight | 911.088 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Deldeprevir (Neceprevir) is a direct-acting anti-HCV drug developed by Achillion. Deldeprevir acts by inhibition of the viral NS3/4A protease. In phase 1b clinical trial for the treatment of chronic HCV infection, the drug was safe and well-tolerated and produced more than a 3 log10 mean maximum reduction in plasma HCV RNA levels in all treated groups. Despite positive results, no development of the drug was reported by Achillion since 2014.
Originator
Approval Year
PubMed
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
TARGET ORGANISM->INHIBITOR |
|
||
|
|
TARGET -> INHIBITOR |
|
Showing 1 to 3 of 3 entries
